Literature DB >> 8656049

Competition between lymphocyte function-associated antigen 1 (CD11a/CD18) and Mac-1 (CD11b/CD18) for binding to intercellular adhesion molecule-1 (CD54).

M Lub1, Y van Kooyk, C G Figdor.   

Abstract

Both human integrin receptors Mac-1 (CD11b/CD18,CR3)and lymphocyte function-associated antigen (LFA)-1 (CD11a/CD18) have been demonstrated to bind human intercellular adhesion molecule-1 (ICAM-1) (CD54). Here we show that LFA-1 and Mac-1 can bind to ICAM-1 in the mouse as well. Interestingly, we observed that binding of murine LFA-1 dominates over Mac-1 for binding to ICAM-1. Using three different murine macrophage cell lines that express distinct levels of LFA-1 and Mac-1 on their cell surface, we could only detect Mac-1-dependent adhesion to ICAM-1 when little or no LFA-1 is expressed on the cell surface. When LFA-1 and Mac-1 are expressed at similar levels, the LFA-1/ICAM-1 interaction dominates over Mac-1/ICAM-1 interaction, indicating that there is a competition of LFA-1 and Mac-1 for ICAM-1 binding.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8656049     DOI: 10.1002/jlb.59.5.648

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  10 in total

1.  Avidity modulation activates adhesion under flow and requires cooperativity among adhesion receptors.

Authors:  Na Ni; Christopher G Kevil; Daniel C Bullard; Dennis F Kucik
Journal:  Biophys J       Date:  2003-12       Impact factor: 4.033

2.  The ICAM-1 antisense oligonucleotide ISIS-3082 prevents the development of postoperative ileus in mice.

Authors:  Frans O The; Wouter J de Jonge; Roel J Bennink; Rene M van den Wijngaard; Guy E Boeckxstaens
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

3.  Kinetics analysis of binding between melanoma cells and neutrophils.

Authors:  Meghan H Hoskins; Cheng Dong
Journal:  Mol Cell Biomech       Date:  2006-06

4.  Monocytes from patients with indeterminate and cardiac forms of Chagas' disease display distinct phenotypic and functional characteristics associated with morbidity.

Authors:  Paulo E A Souza; Manoel O C Rocha; Etel Rocha-Vieira; Cristiane A S Menezes; Andréa C L Chaves; Kenneth J Gollob; Walderez O Dutra
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

Review 5.  Leukocyte integrins and their ligand interactions.

Authors:  Young-Min Hyun; Craig T Lefort; Minsoo Kim
Journal:  Immunol Res       Date:  2009-01-29       Impact factor: 2.829

6.  ICAM-1-expressing neutrophils exhibit enhanced effector functions in murine models of endotoxemia.

Authors:  Abigail Woodfin; Martina Beyrau; Mathieu-Benoit Voisin; Bin Ma; James R Whiteford; Peter L Hordijk; Nancy Hogg; Sussan Nourshargh
Journal:  Blood       Date:  2015-12-08       Impact factor: 22.113

7.  Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha.

Authors:  Weidong Zhang; Zhuang Chen; Fang Li; Huse Kamencic; Bernie Juurlink; John R Gordon; Jim Xiang
Journal:  Immunology       Date:  2003-02       Impact factor: 7.397

8.  Phosphatidylcholine hydroperoxide-induced THP-1 cell adhesion to intracellular adhesion molecule-1.

Authors:  Akira Asai; Fumitaka Okajima; Kiyotaka Nakagawa; Daigo Ibusuki; Kyoko Tanimura; Yasushi Nakajima; Mototsugu Nagao; Mariko Sudo; Taro Harada; Teruo Miyazawa; Shinichi Oikawa
Journal:  J Lipid Res       Date:  2008-12-29       Impact factor: 5.922

9.  Complement receptor 3 deficiency influences lesion progression during Leishmania major infection in BALB/c mice.

Authors:  Cristina R Carter; James P Whitcomb; Jessica A Campbell; Rami M Mukbel; Mary Ann McDowell
Journal:  Infect Immun       Date:  2009-09-21       Impact factor: 3.441

Review 10.  The Inflammatory Response After Ischemic Stroke: Targeting β2 and β1 Integrins.

Authors:  Danielle N Edwards; Gregory J Bix
Journal:  Front Neurosci       Date:  2019-05-28       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.